GB1015618A - Glutarimide therapeutic compositions - Google Patents
Glutarimide therapeutic compositionsInfo
- Publication number
- GB1015618A GB1015618A GB1375863A GB1375863A GB1015618A GB 1015618 A GB1015618 A GB 1015618A GB 1375863 A GB1375863 A GB 1375863A GB 1375863 A GB1375863 A GB 1375863A GB 1015618 A GB1015618 A GB 1015618A
- Authority
- GB
- United Kingdom
- Prior art keywords
- group
- carbon atoms
- less
- phenyl
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
Abstract
The invention comprises compounds of the general formula <FORM:1015618/C2/1> wherein R1 is an alkyl group having more than 1 and less than 10 carbon atoms; R2 is an alkyl group of more than 3 and less than 10 carbon atoms, a phenyl or a benzyl group; R3 is a hydrogen atom, an alkyl or alkenyl group having less than 10 carbon atoms, a phenyl, benzyl or phenylethyl group; R4 is a hydrogen atom, a methyl, ethyl or n-propyl group or R1 and R2 may together form a ring provided by a group -(CH2)4-, -(CH2)5-, -(CH2)4CH-(CH3)- or -(CH2)6- and compounds of the formula <FORM:1015618/C2/2> wherein R1 is an alkyl group having less than 10 carbon atoms; R2 is an alkyl group of more than 1 and less than 10 carbon atoms, a phenyl or a benzyl group; R3 is a hydrogen atom, an alkyl or alkenyl group of less than 10 carbon atoms, a phenyl, benzyl or phenylethyl group and n is 1, 2 or 3 and the pharmaceutically acceptable metal and ammonium salts of the compounds of the general formulae above. The compounds are prepared by condensing cyanoacetic ester with an appropriate ketone and ammonia or a primary amine, or first forming the alkylidene cyanoacetate from 1 mol. each of ketone and cyanoacetic ester and reacting the alkylidene cyanoacetic ester with a further 1 mol. of cyanoacetic ester and an amine or with cyanoacetamide and sodium ethoxide and optionally alkylating the alpha-position in either of the end-products.ALSO:Pharmaceutical compositions in dosage unit form comprise a carrier and a compound selected from either <FORM:1015618/A5-A6/1> or their pharmaceutically acceptable metal and ammonium salts, wherein R1 is an alkyl group of less than 10 carbon atoms; R2 is an alkyl group of less than 10 carbon atoms, a phenyl or benzyl group; R3 is a hydrogen atom, an alkyl or alkenyl group of less than 10 carbon atoms, a phenyl, benzyl or phenylethyl group; R4 is a hydrogen atom, a methyl, ethyl or propyl group; n is 0, 1, 2 or 3 and in Formula I R1 and R2 may together form a ring provided by a group -(CH2)4CH(CH3)-, or -(CH2)6-. The compositions may in addition to the glutarimide contain another active ingredient such as sedatives (e.g. amylobarbitone) and diuretics (e.g. chlorthiazide). The compositions are useful for treating hypertension, and may be in the form of tablets, capsules, cachets, packaged powder, pills, solutions for parenteral administration, suppositories for rectal administration or suspensions for oral administration.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU1641362 | 1962-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1015618A true GB1015618A (en) | 1966-01-05 |
Family
ID=3706340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1375863A Expired GB1015618A (en) | 1962-04-10 | 1963-04-05 | Glutarimide therapeutic compositions |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB1015618A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764640A (en) * | 1984-06-20 | 1988-08-16 | Ciba-Geigy Corporation | Substituted azabicycloheptanes, the use thereof, pharmaceutical preparations that contain these compounds, and processes for the manufacture of these compounds |
| US4839379A (en) * | 1982-12-21 | 1989-06-13 | Ciba-Geigy Corporation | Substituted azabicycloalkanes, the use thereof, pharmaceutical compositions containing them |
| WO1989011856A2 (en) * | 1988-06-03 | 1989-12-14 | The Upjohn Company | Cyclic lactams for cholesterol and atherosclerosis control |
-
1963
- 1963-04-05 GB GB1375863A patent/GB1015618A/en not_active Expired
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839379A (en) * | 1982-12-21 | 1989-06-13 | Ciba-Geigy Corporation | Substituted azabicycloalkanes, the use thereof, pharmaceutical compositions containing them |
| US4764640A (en) * | 1984-06-20 | 1988-08-16 | Ciba-Geigy Corporation | Substituted azabicycloheptanes, the use thereof, pharmaceutical preparations that contain these compounds, and processes for the manufacture of these compounds |
| WO1989011856A2 (en) * | 1988-06-03 | 1989-12-14 | The Upjohn Company | Cyclic lactams for cholesterol and atherosclerosis control |
| WO1989011856A3 (en) * | 1988-06-03 | 1990-01-11 | Upjohn Co | Cyclic lactams for cholesterol and atherosclerosis control |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES481714A1 (en) | Tetrahydropyridine and tetrahydropiperidine derivatives, their acid addition salts, processes for their preparation and pharmaceutical compositions containing them. | |
| ES336256A1 (en) | Azaspirodecanediones and azaspiroundecanediones | |
| PH30061A (en) | Dihydropyridine anti-ischaemic and anti-hypertensive agents | |
| GB1116692A (en) | A method for producing sydnonimine derivatives | |
| US3452040A (en) | 5,5-disubstituted hydantoins | |
| ES8800142A1 (en) | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same. | |
| GB1015618A (en) | Glutarimide therapeutic compositions | |
| GB1023793A (en) | The manufacture of benzodiazepine derivatives | |
| GB964143A (en) | Substituted quinolines | |
| GB1507709A (en) | Benz(de)isoquinoline derivatives | |
| IL85725A (en) | Imidazole derivatives,their manufacture and pharmaceutical compositions containing them | |
| GB964059A (en) | 2,3-polymethylene-quinoline derivatives | |
| NO150316C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE NITROSOURE ADDES | |
| GB1061571A (en) | N,n'-disubstituted piperazines and process for their manufacture | |
| GB953194A (en) | New benzylindene derivatives and method of preparing the same | |
| GB1087840A (en) | 2,4,6-triiodoisophthalic acid derivatives and preparation thereof | |
| GB1058675A (en) | New spiroalkane derivatives | |
| GB1015029A (en) | Pharmaceutical compositions containing barbituric acid derivatives | |
| GB1181295A (en) | Improvements in or relating to Naphthalene Derivatives and the Manufacture Thereof | |
| GB959704A (en) | New indene derivatives and method of preparing the same | |
| GB984707A (en) | Novel benzodiazepine derivatives and a process for the manufacture thereof | |
| ES394409A1 (en) | Triazolobenzodiazepine derivatives | |
| GB1025044A (en) | N-substituted amides and the manufacture thereof | |
| GB1078890A (en) | Novel 1-cycloalkenyl-piperidines and process for the manufacture thereof | |
| GB969027A (en) | Tetrahydrodibenzazocines |